The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma
Open accessAbstract
Despite successful primary tumor treatment, the development of pulmonary metastasis continues to be the most common cause of mortality in patients with osteosarcoma. A conventional drug development path requiring drugs to induce regression of established lesions has not led to improvements for patients with osteosarcoma in more than 30 years. On the basis of our growing understanding of metastasis biology, it is now reasonable and essential that we focus on developing therapeutics that target metastatic progression. To advance this agenda, a meeting of key opinion leaders and experts in the metastasis and osteosarcoma communities was convened in Bethesda, Maryland. The goal of this meeting was to provide a “Perspective” that would establish a preclinical translational path that could support the early evaluation of potential therapeutic agents that uniquely target the metastatic phenotype. Although focused on osteosarcoma, the need for this perspective is shared among many cancer types. The consensus achieved from the meeting included the following: the biology of metastatic progression is associated with metastasis-specific targets/processes that may not influence grossly detectable lesions; targeting of metastasis-specific processes is feasible; rigorous preclinical data are needed to support translation of metastasis-specific agents into human trials where regression of measurable disease is not an expected outcome; preclinical data should include an understanding of mechanism of action, validation of pharmacodynamic markers of effective exposure and response, the use of several murine models of effectiveness, and where feasible the inclusion of the dog with naturally occurring osteosarcoma to define the activity of new drugs in the micrometastatic disease setting. Clin Cancer Res; 20(16); 4200–9. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The tendency of osteosarcoma to metastasize to the lung is an outcome-defining complication that drives patient mortality and challenges clinicians.
“The tendency for osteosarcoma to metastasize to the lung is an outcome-defining complication that drives patient mortality and challenges clinicians 50 .”
From Osteosarcoma (2022) · cites this paper as [50]
Companion cell lines with enhanced lung colonization capacity have enabled study of metastasis-driving mechanisms.
“Companion cell lines with enhanced lung colonization capacity, such as SaOS2-LM7, MG63.3 and 143B 209,210,211 , have enabled the study of metastasis-driving mechanisms 50,212 .”
From Osteosarcoma (2022) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor Self-Seeding by Circulating Cancer Cells
Kim, M.-Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H.-F., Norton, L., & Massagué, J. (2009) · Cell · doi:10.1016/j.cell.2009.11.025 · Cited by 1,335
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313
Multistep Nature of Metastatic Inefficiency
Luzzi, K. J., MacDonald, I. C., Schmidt, E. E., Kerkvliet, N. I., Morris, V. L., Chambers, A. F., & Groom, A. C. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65628-3 · Cited by 1,246
Real-time imaging reveals the single steps of brain metastasis formation.
Kienast, Y., von Baumgarten, L., Fuhrmann, M., Klinkert, W. E. F., Goldbrunner, R., Herms, J., & Winkler, F. (2010) · Nature Medicine · doi:10.1038/nm.2072 · Cited by 1,138
New signals from the invasive front
Christofori, G. (2006) · Nature · doi:10.1038/nature04872 · Cited by 1,018
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752
Self-citationMetastasis: recent discoveries and novel treatment strategies
Eccles, S. A., & Welch, D. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60781-8 · Cited by 737
Self-citationPreparing the “Soil”: The Premetastatic Niche
Kaplan, R. N., Rafii, S., & Lyden, D. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2407 · Cited by 681
Self-citationTranslation of new cancer treatments from pet dogs to humans
Paoloni, M., & Khanna, C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2273 · Cited by 668
Self-citationSpontaneously Occurring Tumors of Companion Animals as Models for Human Cancer
Vail, D. M., & MacEwen, E. G. (2000) · Cancer Investigation · doi:10.3109/07357900009012210 · Cited by 533
Buddingh, E. P., Kuijjer, M. L., Duim, R. A. J., Bürger, H., Agelopoulos, K., Myklebost, O., Serra, M., Mertens, F., Hogendoorn, P. C. W., Lankester, A. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2047 · Cited by 508
Inhibition of Metastatic Outgrowth from Single Dormant Tumor Cells by Targeting the Cytoskeleton
Barkan, D., Kleinman, H. K., Simmons, J. L., Asmussen, H., Kamaraju, A. K., Hoenorhoff, M. J., Liu, Z.-Y., Costes, S. V., Cho, E. H., Lockett, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6849 · Cited by 430
Self-citationBrain metastases as preventive and therapeutic targets
Steeg, P. S., Camphausen, K. A., & Smith, Q. R. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3053 · Cited by 367
Self-citationMarino, N., Woditschka, S., Reed, L. T., Nakayama, J., Mayer, M., Wetzel, M., & Steeg, P. S. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.06.012 · Cited by 315
Self-citationCanine tumor cross-species genomics uncovers targets linked to osteosarcoma progression
Paoloni, M., Davis, S., Lana, S., Withrow, S., Sangiorgi, L., Picci, P., Hewitt, S., Triche, T., Meltzer, P., & Khanna, C. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-625 · Cited by 291
Self-citationEffect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the Brain
Gril, B., Palmieri, D., Bronder, J. L., Herring, J. M., Vega-Valle, E., Feigenbaum, L., Liewehr, D. J., Steinberg, S. M., Merino, M. J., Rubin, S. D., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn216 · Cited by 284
Self-citationMacEwen, E. G., Kurzman, I. D., ROSENTHAL, R. C., Smith, B. W., Manley, P. A., Roush, J. K., & Howard, P. E. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.12.935 · Cited by 227
Cancer Dormancy: A Model of Early Dissemination and Late Cancer Recurrence
Páez, D., LaBonte, M. J., Bohanes, P. O., Zhang, W., Benhanim, L., Ning, Y., Wakatsuki, T., Loupakis, F., & Lenz, H. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2186 · Cited by 215
Critical Steps in Hematogenous Metastasis
Chambers, A. F., Naumov, G. N., Varghese, H. J., Nadkarni, K. V., MacDonald, I. C., & Groom, A. C. (2001) · Surgical Oncology Clinics of North America · doi:10.1016/s1055-3207(18)30063-2 · Cited by 210
Cancer metastasis as a therapeutic target
Sleeman, J. P., & Steeg, P. S. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.039 · Cited by 198
Self-citationCritical steps in hematogenous metastasis: an overview.
Chambers, A. F., Naumov, G. N., Varghese, H. J., Nadkarni, K. V., MacDonald, I. C., & Groom, A. C. (2001) · PubMed · Cited by 191
Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells
Bulut, G., Hong, S.-H., Chen, K., Beauchamp, E. M., Rahim, S., Kosturko, G. W., Glasgow, E., Dakshanamurthy, S., Lee, H.-S., Daar, I., et al. (2012) · Oncogene · doi:10.1038/onc.2011.245 · Cited by 179
Self-citationMechanisms of Cancer Cell Metastasis to the Bone: A Multistep Process
Patel, L. R., Camacho, D. F., Shiozawa, Y., Pienta, K. J., & Taichman, R. S. (2011) · Future Oncology · doi:10.2217/fon.11.112 · Cited by 159
Kleinerman, E. S., Jia, S. F., Griffin, J., Seibel, N. L., Benjamin, R. S., & Jaffe, N. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.8.1310 · Cited by 157
Self-citationDisseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ
Sänger, N., Effenberger, K. E., Riethdorf, S., van Haasteren, V., Gauwerky, J. F. H., Wiegratz, I., Strebhardt, K., Kaufmann, M., & Pantel, K. (2011) · International Journal of Cancer · doi:10.1002/ijc.25895 · Cited by 153
Mundy, G. R. (2008) · Bone · doi:10.1016/j.bone.2007.12.198 · Cited by 147
Kurzman, I. D., MacEwen, E. G., ROSENTHAL, R. C., Fox, L. E., Keller, E. T., Helfand, S. C., Vail, D. M., Dubielzig, R. R., Madewell, B. R., & Rodriguez, C. O. (1995) · PubMed · Cited by 142
Kleinerman, E. S., Erickson, K. L., Schroit, A. J., Fogler, W. E., & Fidler, I. J. (1983) · PubMed · Cited by 141
Self-citationRevisiting the seed and soil in cancer metastasis
Mendoza, M., & Khanna, C. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.01.015 · Cited by 126
Self-citationSRC kinase inhibition: Targeting bone metastases and tumor growth in prostate and breast cancer
Fred Saad, C., & Lipton, A. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.11.005 · Cited by 126
Anderson, P. M., Markovic, S. N., Sloan, J. A., Clawson, M. L., Wylam, M. E., Arndt, C. A. S., Smithson, W. A., Burch, P. A., Gornet, M. E., & Rahman, E. (1999) · PubMed · Cited by 118
Paoloni, M. C., Tandle, A. T., Mazcko, C. N., Hanna, E., Kachala, S. S., LeBlanc, A. K., Newman, S. J., Vail, D. M., Henry, C. J., Thamm, D. H., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004972 · Cited by 118
Self-citationEfficacy of Liposomal Muramyl Tripeptide (CGP 19835A) in the Treatment of Relapsed Osteosarcoma
Kleinerman, E. S., Gano, J. B., Johnston, D. A., Benjamin, R. S., & Jaffe, N. (1995) · American Journal of Clinical Oncology · doi:10.1097/00000421-199504000-00001 · Cited by 116
Self-citationPhase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients.
Murray, J. L., Kleinerman, E. S., Cunningham, J. E., Tatom, J. R., Andrejcio, K., Lepe-Zuniga, J. L., LAMKI, L. M., Rosenblum, M. G., Frost, H., & Gutterman, J. U. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.12.1915 · Cited by 109
Self-citationDrug development against metastasis-related genes and their pathways: A rationale for cancer therapy
Iiizumi, M., Liu, W., Pai, S. K., Furuta, E., & Watabe, K. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.07.002 · Cited by 104
Hematopoietic Stem Cell Niche Is a Potential Therapeutic Target for Bone Metastatic Tumors
Shiozawa, Y., Pienta, K. J., & Taichman, R. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2505 · Cited by 102
Modeling metastasis biology and therapy in real time in the mouse lung
Mendoza, A., Hong, S.-H., Osborne, T., Khan, M. A., Campbell, K., Briggs, J., Eleswarapu, A., Buquo, L., Ren, L., Hewitt, S. M., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40252 · Cited by 92
Self-citationSteeg, P. S. (2012) · Nature · doi:10.1038/485s58a · Cited by 82
Self-citationOncology of infancy and childhood
Orkin, S. H. (2009) · Elsevier eBooks · Cited by 80
Arndt, C. A. S., Koshkina, N., Inwards, C. Y., Hawkins, D. S., Krailo, M., Villaluna, D., Anderson, P. M., Goorin, A. M., Blakely, M. L., Bernstein, M. L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0662 · Cited by 79
Self-citationSugarbaker, E. V., Cohen, A. M., & Ketcham, A. S. (1971) · Annals of Surgery · doi:10.1097/00000658-197108000-00001 · Cited by 78
Anderson, P. M., Meyers, P. A., Kleinerman, E. S., Venkatakrishnan, K., Hughes, D. P. M., Herzog, C. E., Huh, W. W., Sutphin, R. M., Vyas, Y. M., Shen, V., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24686 · Cited by 75
Self-citationKleinerman, E. S., Murray, J. L., Snyder, J. S., Cunningham, J. E., & Fidler, I. J. (1989) · PubMed · Cited by 74
Self-citationCross Talk from Pets to People: Translational Osteosarcoma Treatments
Withrow, S. J., & Wilkins, R. M. (2010) · ILAR Journal · doi:10.1093/ilar.51.3.208 · Cited by 73
Self-citationMolecular mechanisms of metastasis
Hoon, D. S. �., Kitago, M., Kim, J., Mori, T., Piris, A., Masterpol, K. S., Mihm, M. C., Nathanson, S. D., Padera, T. P., Chambers, A. F., et al. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-8500-x · Cited by 69
Kleinerman, E. S., Raymond, A. K., Bucana, C. D., Jaffe, N., Harris, M. B., Krakoff, I. H., Benjamin, R. S., & Fidler, I. J. (1992) · Cancer Immunology Immunotherapy · doi:10.1007/bf01741788 · Cited by 63
Self-citationCombination Therapy with Ifosfamide and Liposome-Encapsulated Muramyl Tripeptide
Kleinerman, E. S., Meyers, P. A., Raymond, A. K., Gano, J. B., Jia, S.-F., & Jaffe, N. (1995) · Journal of Immunotherapy · doi:10.1097/00002371-199504000-00007 · Cited by 57
Self-citationSampson, V. B., Gorlick, R. G., Kamara, D. F., & Kolb, E. A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00132 · Cited by 51
Self-citationMetastasis-suppressor genes in clinical practice: lost in translation?
Shoushtari, A. N., Szmulewitz, R. Z., & Rinker-Schaeffer, C. W. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.65 · Cited by 50
Genetically engineered mouse models and human osteosarcoma
Ng, A. J., Mutsaers, A. J., Baker, E. K., & Walkley, C. R. (2012) · Clinical Sarcoma Research · doi:10.1186/2045-3329-2-19 · Cited by 45
Rao, B., Han, M.-Y., Wang, L., Gao, X., Huang, J. C., Huang, M., Liu, H., & Wang, J. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-17 · Cited by 41
Tait, C. R., Dodwell, D. J., & Horgan, K. J. (2004) · The Journal of Pathology · doi:10.1002/path.1544 · Cited by 38
Metastasis: The rude awakening
Rice, J. (2012) · Nature · doi:10.1038/485s55a · Cited by 31
Maeda, M., Knowles, R. D., & Kleinerman, E. S. (1991) · Cancer Communications · doi:10.3727/095535491820873740 · Cited by 30
Self-citationA Dose-Escalation Study of Aerosolized Sargramostim in the Treatment of Metastatic Melanoma
Markovic, S. N., Suman, V. J., Nevala, W. K., Geeraerts, L., Creagan, E. T., Erickson, L. A., Rowland, K. M., Morton, R. F., Horvath, W. L., & Pittelkow, M. R. (2008) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e318173a536 · Cited by 28
Bridging the Gap Between Experimental Animals and Humans in Osteosarcoma
Withrow, S. J., & Khanna, C. (2009) · Cancer treatment and research · doi:10.1007/978-1-4419-0284-9_24 · Cited by 27
Self-citationArcaroli, J. J., Quackenbush, K. S., Dasari, A. N., Powell, R. W., McManus, M. C., Tan, A. C., Foster, N. R., Picus, J., Wright, J., Nallapareddy, S., et al. (2012) · Cancer Medicine · doi:10.1002/cam4.27 · Cited by 23
Fidler, I. J., Fan, D., & Ichinose, Y. (1989) · PubMed · Cited by 23
Bruland, Ø. S., Høifødt, H. K., Hall, K. S., Smeland, S., & Fodstad, Ø. (2009) · Cancer treatment and research · doi:10.1007/978-1-4419-0284-9_30 · Cited by 18
Hisano, G., & Fidler, I. (1982) · Cancer Immunology Immunotherapy · doi:10.1007/bf00200168 · Cited by 17
Landmann, R. M., Obrist, R., Denz, H. A., Ludwig, C., Frost, H., Wesp, M., Rordorf, C., Towbin, H., Gygax, D., Tarcsay, L., et al. (1993) · Biotherapy · doi:10.1007/bf01878149 · Cited by 17
Defining the biologic role of genes that regulate prostate cancer metastasis
Rinker-Schaeffer, C. W., Welch, D. R., & Sokoloff, M. H. (2000) · Current Opinion in Urology · doi:10.1097/00042307-200009000-00006 · Cited by 16
Self-citationRzab, M. (1980) · Amaranthus · Cited by 6
Heikenwälder, M. F., & Borsig, L. (2012) · Future Oncology · doi:10.2217/fon.12.163 · Cited by 6
&NA; (1987) · Transplantation · doi:10.1097/00007890-198704000-00028 · Cited by 4
LeGrue, S. J., Saiki, I., Romerdahl, C. A., & Fidler, I. J. (1987) · PubMed · Cited by 3
Flagged first, then by citations
Cited by
Sorted by citations
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
Isakoff, M. S., Bielack, S., Meltzer, P. S., & Gorlick, R. G. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4895 · Cited by 1,578
Self-citationBeird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Self-citationOsteosarcoma, Chondrosarcoma, and Chordoma
Whelan, J., & Davis, L. E. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.1743 · Cited by 477
Comparative oncology: what dogs and other species can teach us about humans with cancer
Schiffman, J. D., & Breen, M. (2015) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2014.0231 · Cited by 445
Metastatic osteosarcoma: a challenging multidisciplinary treatment
Meazza, C., & Scanagatta, P. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1168697 · Cited by 300
Future directions in the treatment of osteosarcoma
Bishop, M. W., Janeway, K. A., & Gorlick, R. G. (2015) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000298 · Cited by 266
Self-citationNovel Insights and Therapeutic Interventions for Pediatric Osteosarcoma
Kager, L., Tamamyan, G., & Bielack, S. (2016) · Future Oncology · doi:10.2217/fon-2016-0261 · Cited by 242
Osteosarcoma: Accelerating Progress Makes for a Hopeful Future
Saraf, A. J., Fenger, J. M., & Roberts, R. D. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00004 · Cited by 237
Han, Y., Guo, W., Ren, T., Huang, Y., Wang, S., Liu, K., Zheng, B., Kang, Y., Zhang, H., & Liang, X. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.011 · Cited by 190
Mason, N. J., Gnanandarajah, J. S., Engiles, J. B., Gray, F., Laughlin, D., Gaurnier-Hausser, A., Wallecha, A., Huebner, M., & Paterson, Y. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0088 · Cited by 178
Liu, W., Zhao, Y., Wang, G., Feng, S., Ge, X., Ye, W., Wang, Z., Zhu, Y., Cai, W., Bai, J., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102344 · Cited by 174
Current and Future Treatment Strategies for Rhabdomyosarcoma
Chen, C. Y., García, H. D., Scheer, M., & Henssen, A. G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01458 · Cited by 179
Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies
Morrow, J. J., & Khanna, C. (2015) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2015013713 · Cited by 173
Self-citationDevelopment of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy
Mills, C. C., Kolb, E. A., & Sampson, V. B. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2782 · Cited by 160
Fritzsching, B., Fellenberg, J., Moskovszky, L. E., Sápi, Z., Krenács, T., Machado, I., Poeschl, J., Lehner, B., Szendrői, M., Bosch, A. L., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.990800 · Cited by 140
Ligon, J. A., Choi, W., Cojocaru, G., Fu, W., Hsiue, E. H.-C., Oke, T. F., Siegel, N., Fong, M. H., Ladle, B., Pratilas, C. A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001772 · Cited by 124
Roberts, R. D., Lizardo, M. M., Reed, D. R., Hingorani, P., Glover, J., Allen‐Rhoades, W., Fan, T., Khanna, C., Sweet‐Cordero, E. A., Cash, T., et al. (2019) · Cancer · doi:10.1002/cncr.32351 · Cited by 127
Self-citationSIRT7 inactivation reverses metastatic phenotypes in epithelial and mesenchymal tumors
Malik, S., Villanova, L., Tanaka, S., Aonuma, M., Roy, N., Berber, E., Pollack, J. R., Michishita-Kioi, E., & Chua, K. F. (2015) · Scientific Reports · doi:10.1038/srep09841 · Cited by 120
Glutaminase-1 (GLS1) inhibition limits metastatic progression in osteosarcoma
Ren, L., Ruiz‐Rodado, V., Dowdy, T., Huang, S., Issaq, S. H., Beck, J. A., Wang, H., Hoang, C. D., Lita, A., Larion, M., et al. (2020) · Cancer & Metabolism · doi:10.1186/s40170-020-0209-8 · Cited by 102
Companion animals in comparative oncology: One Medicine in action
Garden, O. A., Volk, S. W., Mason, N. J., & Perry, J. A. (2018) · The Veterinary Journal · doi:10.1016/j.tvjl.2018.08.008 · Cited by 98
Regan, D. P., Chow, L., Das, S., Haines, L., Palmer, E., Kurihara, J. N., Coy, J. W., Mathias, A., Thamm, D. H., Gustafson, D. L., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2105 · Cited by 92
Chen, L., Liu, J.-F., Lu, Y., He, X., Zhang, C., & Zhou, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.642144 · Cited by 90
Fan, T. M., Roberts, R. D., & Lizardo, M. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00013 · Cited by 90
Self-citationIL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis
Gross, A. C., Cam, H., Phelps, D. A., Saraf, A. J., Bid, H. K., Cam, M., London, C. A., Winget, S. A., Arnold, M. A., Brandolini, L., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.99791 · Cited by 82
Self-citationYin, Q., Tang, L., Cai, K., Tong, R., Sternberg, R., Yang, X., Dobrucki, L. W., Borst, L. B., Kamstock, D. A., Song, Z., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603316113 · Cited by 82
Self-citationBailey, K. M., Cost, C. R., Davis, I. J., Bender, J. G., Grohar, P. J., Houghton, P. J., Isakoff, M. S., Stewart, E. S., Laack, N. N., Yustein, J. T., et al. (2019) · F1000Research · doi:10.12688/f1000research.18139.1 · Cited by 79
Self-citationGoldstein, S. D., Trucco, M., Guzman, W. B., Hayashi, M., & Loeb, D. M. (2016) · Oncotarget · doi:10.18632/oncotarget.8522 · Cited by 78
Canine and murine models of osteosarcoma
Beck, J. A., Ren, L., Huang, S., Berger, E. P., Bardales, K., Mannheimer, J., Mazcko, C. N., & LeBlanc, A. K. (2022) · Veterinary Pathology · doi:10.1177/03009858221083038 · Cited by 83
Defining the Value of a Comparative Approach to Cancer Drug Development
LeBlanc, A. K., Mazcko, C. N., & Khanna, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2347 · Cited by 73
Self-citationGupte, A., Baker, E. K., Wan, S.-S., Stewart, E. A., Loh, A. H. P., Shelat, A. A., Gould, C. M., Chalk, A. M., Taylor, S., Lackovic, K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3026 · Cited by 70
Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis
Murphy, B., Yin, H., Maris, J. M., Kolb, E. A., Gorlick, R., Reynolds, C. P., Kang, M. H., Keir, S. T., Kurmasheva, R. T., Dvorchik, I., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0122 · Cited by 69
Self-citationHendricks, W. P. D., Zismann, V., Sivaprakasam, K., Legendre, C., Poorman, K. A., Tembe, W., Perdigones, N., Kiefer, J., Liang, W. S., DeLuca, V. J., et al. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007589 · Cited by 67
Self-citationLeBlanc, A. K., Mazcko, C. N., Cherukuri, A., Berger, E. P., Kisseberth, W. C., Brown, M. E., Lana, S. E., Weishaar, K. M., Flesner, B. K., Bryan, J. N., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0315 · Cited by 55
Self-citationOsteogenic Sarcoma: A 21st Century Review
Osasan, S. A., Zhang, M.-Y., Shen, F., Paul, P., Persad, S., & Sergi, C. M. (2016) · Anticancer Research · doi:10.21873/anticanres.10982 · Cited by 55
Macklin, R., Wang, H., Loo, D., Martin, S., Cumming, A., Cai, N., Lane, R. E., Saenz-Ponce, N., Topkas, E., Inder, K. L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9781 · Cited by 55
Bishop, M. W., Chang, Y., Krailo, M. D., Meyers, P. A., Provisor, A. J., Schwartz, C. L., Marina, N. M., Teot, L. A., Gebhardt, M. C., Gorlick, R., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26034 · Cited by 52
Self-citationComparative Aspects of Osteosarcoma Pathogenesis in Humans and Dogs
Fan, T. M., & Khanna, C. (2015) · Veterinary Sciences · doi:10.3390/vetsci2030210 · Cited by 54
Self-citationLizardo, M. M., Morrow, J. J., Miller, T. E., Hong, E. S., Ren, L., Mendoza, A., Halsey, C. H., Scacheri, P. C., Helman, L. J., & Khanna, C. (2016) · Neoplasia · doi:10.1016/j.neo.2016.09.001 · Cited by 50
Self-citationFoltz, J. A., Somanchi, S. S., Yang, Y., Aquino‐López, A., Bishop, E. E., & Lee, D. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00521 · Cited by 49
Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis
Murahari, S., Jalkanen, A., Kulp, S. K., Chen, C., Modiano, J. F., London, C. A., & Kisseberth, W. C. (2017) · BMC Cancer · doi:10.1186/s12885-017-3046-6 · Cited by 47
Mannheimer, J., Tawa, G. J., Gerhold, D. L., Braisted, J. C., Sayers, C. M., McEachron, T. A., Meltzer, P. S., Mazcko, C. N., Beck, J. A., & LeBlanc, A. K. (2023) · Communications Biology · doi:10.1038/s42003-023-05208-z · Cited by 49
Self-citationSchott, C. R., Koehne, A. L., Sayles, L. C., Young, E. P., Luck, C., Yu, K., Lee, A. G., Breese, M. R., Leung, S. G., Xu, H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0873 · Cited by 47
Goldstein, S. D., Hayashi, M., Albert, C. M., Jackson, K. W., & Loeb, D. M. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9738-x · Cited by 45
Comparative Immunology and Immunotherapy of Canine Osteosarcoma
Mason, N. J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_14 · Cited by 46
Liu, T., Ma, Q., Zhang, Y., Wang, X., Xu, K., Kang, Y., Dong, W., Fan, Q., Zhang, Y., & Qiu, X. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1795-7 · Cited by 43
Tornín, J., Villasante, A., Solé‐Martí, X., Ginebra, M., & Canal, C. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.12.437 · Cited by 43
Maloney, C. W., Kallis, M. P., Edelman, M. C., Tzanavaris, C., LESSER, M. L., Soffer, S. Z., Symons, M. H., & Steinberg, B. M. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0903 · Cited by 41
Maloney, C. W., Edelman, M. C., Kallis, M. P., Soffer, S. Z., Symons, M. H., & Steinberg, B. M. (2018) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999.0000000000000291 · Cited by 40
Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma
Landuzzi, L., Manara, M. C., Lollini, P.-L., & Scotlandi, K. (2021) · Cells · doi:10.3390/cells10020416 · Cited by 39
Molecular profiling of childhood cancer: Biomarkers and novel therapies
Saletta, F., Wadham, C., Ziegler, D. S., Marshall, G. M., Haber, M., McCowage, G. B., Norris, M. D., & Byrne, J. A. (2014) · BBA Clinical · doi:10.1016/j.bbacli.2014.06.003 · Cited by 47
Rivera-Valentin, R. K., Zhu, L., & Hughes, D. P. M. (2015) · Pediatric Drugs · doi:10.1007/s40272-015-0134-4 · Cited by 40
Talbot, L. J., Chabot, A., Funk, A., Nguyen, P., Wagner, J., Ross, A. B., Tillman, H. S., Davidoff, A. M., Gottschalk, S. M., & DeRenzo, C. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.691741 · Cited by 39
Loh, A. H. P., Stewart, E., Bradley, C. L., Chen, X., Daryani, V., Stewart, C. F., Calabrese, C., Funk, A., Miller, G., Karlstrom, A., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2018.10.033 · Cited by 36
Biteau, K., Guiho, R., Chatelais, M., Taurelle, J., Chesneau, J., Corradini, N., Heymann, D., & Rédiní, F. (2016) · PubMed Central · Cited by 36
Jacques, C., Renema, N., Lézot, F., Ory, B., Walkley, C. R., Grigoriadis, A. E., & Heymann, D. (2018) · Journal of bone oncology · doi:10.1016/j.jbo.2018.02.004 · Cited by 36
Dog breeds and conformations predisposed to osteosarcoma in the UK: a VetCompass study
O'Neill, D. G., Edmunds, G. L., Urquhart-Gilmore, J., Church, D. B., Rutherford, L., Smalley, M. J., & Brodbelt, D. C. (2023) · Canine Medicine and Genetics · doi:10.1186/s40575-023-00131-2 · Cited by 38
Targeting XIST induced apoptosis of human osteosarcoma cells by activation of NF-kB/PUMA signal
Gao, W., Gao, J., Chen, L., Ren, Y., & Ma, J. (2019) · Bioengineered · doi:10.1080/21655979.2019.1631104 · Cited by 34
Rajan, S., Ringwalt, E. M., McAloney, C. A., Vetter, T. A., Cam, M., Gross, A. C., Taslim, C., Wang, M., Cannon, M. V., Oles, A. R., et al. (2023) · BMC Biology · doi:10.1186/s12915-023-01593-3 · Cited by 44
LDHB may be a significant predictor of poor prognosis in osteosarcoma.
Li, C., Chen, Y., Bai, P., Wang, J., Liu, Z., Wang, T., & Cai, Q. (2016) · PubMed Central · Cited by 34
Heng, L., Jia, Z., Bai, J., Zhang, K., Zhu, Y., Ma, J., Zhang, J., & Duan, H. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6286 · Cited by 31
PLOD1 Is a Prognostic Biomarker and Mediator of Proliferation and Invasion in Osteosarcoma
Jiang, H., Guo, W., Yuan, S., & Song, L. (2020) · BioMed Research International · doi:10.1155/2020/3418398 · Cited by 28
Patil, S. L., Palat, A., Pan, Y., Rajapakshe, K., Mirchandani, R., Bondesson, M., Yustein, J. T., Coarfa, C., & Gunaratne, P. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-55170-2 · Cited by 30
Isakoff, M. S., Goldsby, R. E., Villaluna, D., Krailo, M., Hingorani, P., Collier, A. B., Morris, C. D., Kolb, E. A., Doski, J. J., Womer, R. B., et al. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27524 · Cited by 29
Self-citationEfficacy of glycogen synthase kinase-3β targeting against osteosarcoma via activation of β-catenin
Shimozaki, S., Yamamoto, N., Domoto, T., Nishida, H., Hayashi, K., Kimura, H. J., Takeuchi, A., Miwa, S., Igarashi, K., Kato, T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12781 · Cited by 30
What is the best clinical approach to recurrent/refractory osteosarcoma?
Meazza, C., Bastoni, S., & Scanagatta, P. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1760848 · Cited by 28
A 3D Collagen-Based Bioprinted Model to Study Osteosarcoma Invasiveness and Drug Response
Pellegrini, E., Desando, G., Petretta, M., Cellamare, A., Cristalli, C., Pasello, M., Manara, M. C., Grigolo, B., & Scotlandi, K. (2022) · Polymers · doi:10.3390/polym14194070 · Cited by 30
Morrow, J. J., Mendoza, A., Koyen, A., Lizardo, M. M., Ren, L., Waybright, T. J., Hansen, R. J., Gustafson, D. L., Zhou, M., Fan, T. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0326 · Cited by 27
Self-citationPacenta, H. L., Allen‐Rhoades, W. A., Langenau, D. M., Houghton, P. J., Keller, C., Heske, C. M., Deel, M. D., Linardic, C. M., Shern, J. F., Stewart, E. A., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071416 · Cited by 27
Self-citationRe-calculating! Navigating through the osteosarcoma treatment roadblock
McGuire, J., Utset‐Ward, T. J., Reed, D. R., & Lynch, C. C. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.004 · Cited by 26
ΔNp63 mediates cellular survival and metastasis in canine osteosarcoma
Cam, M., Gardner, H. L., Roberts, R. D., Fenger, J. M., D, D. C. G., London, C. A., & Çam, H. (2016) · Oncotarget · doi:10.18632/oncotarget.10406 · Cited by 25
Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer
Doyle, H. A., Gee, R. J., Masters, T. D., Gee, C. R., Booth, C. J., Peterson-Roth, E., Koski, R. A., Helfand, S. C., Price, L., Bascombe, D., et al. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101205 · Cited by 25
Tierny, D., Serres, F. J., Segaoula, Z., Bemelmans, I., Bouchaert, E., Pétain, A., Brel, V., Couffin, S., Marchal, T., Nguyen, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3174 · Cited by 25
Challenges and Opportunities for Childhood Cancer Drug Development
Houghton, P. J., & Kurmasheva, R. T. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.016972 · Cited by 25
Self-citationHennessy, M., Wahba, A., Felix, K., Cabrera, M., Segura, M. G., Kundra, V., Ravoori, M. K., Stewart, J., Kleinerman, E. S., Jensen, V. B., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33382 · Cited by 21
Self-citationCollier, C. D., Wirtz, E. C., Knafler, G. J., Morris, W. Z., Getty, P. J., & Greenfield, E. M. (2018) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999.0000000000000059 · Cited by 22
MicroRNA-761 suppresses tumor progression in osteosarcoma via negatively regulating ALDH1B1
Wang, X., Li, C., Yao, W., Tian, Z., Liu, Z., & Ge, H. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118544 · Cited by 22
Glover, J., Krailo, M., Tello, T., Marina, N. M., Janeway, K. A., Barkauskas, D. A., Fan, T. M., Gorlick, R. G., Khanna, C., & the COG Osteosarcoma Biology Group (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25346 · Cited by 22
Self-citationUpregulation of ALDH1B1 promotes tumor progression in osteosarcoma
Wang, X., Yu, Y. H., He, Y., Cai, Q., Gao, S., Yao, W., Liu, Z., Tian, Z., Han, Q., Wang, W., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23506 · Cited by 21
Lung fibrosis is a novel therapeutic target to suppress lung metastasis of osteosarcoma
Yui, Y., Kumai, J., Watanabe, K., Wakamatsu, T., & Sasagawa, S. (2022) · International Journal of Cancer · doi:10.1002/ijc.34008 · Cited by 23
Pharmacological prevention of surgery-accelerated metastasis in an animal model of osteosarcoma
Kallis, M. P., Maloney, C. W., Blank, B. A., Soffer, S. Z., Symons, M. H., & Steinberg, B. M. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02348-2 · Cited by 20
Fan, T. M., & Selting, K. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2018.00680 · Cited by 21
Self-citationLizardo, M. M., & Sorensen, P. H. (2018) · Journal of Visualized Experiments · doi:10.3791/56332 · Cited by 19
Self-citationBoyland, R. F., Amin, S., Shostrom, V., Zheng, C., Allison, J., & Lin, C. H. (2025) · BMC Cancer · doi:10.1186/s12885-025-13496-3 · Cited by 20
Davis, L. E., Jeng, S., Svalina, M. N., Huang, E., Pittsenbarger, J., Cantor, E. L., Berlow, N., Séguin, B., Mansoor, A., McWeeney, S. K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19532 · Cited by 19
New Small Molecules Targeting Apoptosis and Cell Viability in Osteosarcoma
Maugg, D., Rothenaigner, I., Schorpp, K., Potukuchi, H. K., Korsching, E., Baumhoer, D., Hadian, K., Smida, J., & Nathrath, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129058 · Cited by 19
Singe nucleotide polymorphisms in osteosarcoma: Pathogenic effect and prognostic significance
Asnafi, A. A., Behzad, M. M., Ghanavat, M., Shahjahani, M., & Saki, N. (2018) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2018.12.002 · Cited by 17
Chen, X., Cates, J., Du, Y.-C., Jain, A., Jung, S. Y., Li, X.-N., Hicks, J. M., & Man, T. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12624 · Cited by 17
Whittle, S. B., Offer, K., Roberts, R. D., LeBlanc, A. K., London, C. A., Majzner, R. G., Huang, A. Y.-C., Houghton, P. J., Sweet-Cordero, A., Grohar, P. J., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29188 · Cited by 18
Self-citationBreast Cancer Metastasis Suppressor 1 (BRMS1)
Welch, D. R., Manton, C. A., & Hurst, D. R. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.05.003 · Cited by 16
Self-citationNass, S. J., & Gorby, H. (2015) · Cited by 16
KMT2C modulates migration and invasion processes in osteosarcoma cell lines
Chiappetta, C., Carletti, R., Rocca, C. D., & Cristofano, C. D. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152534 · Cited by 15
Osteosarcoma through the Lens of Bone Development, Signaling, and MicroenvironmentPreprint
Young, E. P., Marinoff, A. E., López-Fuentes, E., & Sweet-Cordero, A. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041635 · Cited by 14
Klosowski, M. L., Haines, L. A., Alfino, L., McMellen, A. N., Leibowitz, M. J., & Regan, D. P. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1130215 · Cited by 15
Mason, N. J., Selmic, L. E., Ruple, A., London, C. A., Barber, L. G., Weishaar, K. M., Perry, J. A., Mahoney, J., Flesner, B. K., Bryan, J. N., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.02.023 · Cited by 14
Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming
Yang, Y., Peng, Z., Flores, E. R., & Kleinerman, E. S. (2022) · Cancers · doi:10.3390/cancers14174310 · Cited by 15
Self-citationRapid Protocol Enrollment in Osteosarcoma: A Report From the Children's Oncology Group
Isakoff, M. S., Goldsby, R. E., Villaluna, D., Krailo, M., Gorlick, R. G., Doski, J. J., Womer, R. B., & Janeway, K. A. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25754 · Cited by 14
Self-citationMai, W., Kong, L., Yu, H., Bao, J., Song, C., & Qu, G. (2021) · Bioscience Reports · doi:10.1042/bsr20193514 · Cited by 13
Evaluation of F8-TNF-α in Models of Early and Progressive Metastatic Osteosarcoma
Robl, B., Botter, S. M., Boro, A., Meier, D., Neri, D., & Fuchs, B. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.02.005 · Cited by 13
Roberts, B. K., Li, D. I., Somerville, C. C., Matta, B., Jha, V. J., Steinke, A. M., Brune, Z., Blanc, L., Soffer, S. Z., & Barnes, B. J. (2024) · Scientific Reports · doi:10.1038/s41598-024-66168-w · Cited by 15
Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo
Watanabe, K., Yui, Y., Sasagawa, S., Suzuki, K., Kanamori, M., Yasuda, T., & Kimura, T. (2019) · Oncotarget · doi:10.18632/oncotarget.26536 · Cited by 12
Metadata
- Authors
- Khanna, C., Fan, T. M., Gorlick, R., Helman, L. J., Kleinerman, E. S., Adamson, P. C., Houghton, P. J., Tap, W. D., Welch, D. R., Steeg, P. S., Merlino, G., Sorensen, P. H. B., Meltzer, P., Kirsch, D. G., Janeway, K. A., Weigel, B., Randall, L., Withrow, S. J., Paoloni, M., Kaplan, R., Teicher, B. A., Seibel, N. L., Smith, M., Üren, A., Patel, S. R., Trent, J., Savage, S. A., Mirabello, L., Reinke, D., Barkaukas, D. A., Krailo, M., & Bernstein, M.
- Affiliations
- National Institutes of Health (US)
- University of Illinois Urbana-Champaign (US)
- Albert Einstein College of Medicine (US)
- 17Cancer Biology and
- Children's Hospital of Philadelphia (US)
- Nationwide Children's Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Kansas Medical Center (US)
- University of British Columbia (CA)
- Duke Medical Center (US)
- Harvard University (US)
- University of Minnesota (US)
- University of Utah (US)
- Colorado State University (US)
- Georgetown University Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Translational Genomics Research Institute (US)
- University of Michigan (US)
- Children's Oncology Group (US)
- University of Southern California (US)
- Dalhousie University (CA)
- Corresponding author
- Fan, Timothy M.
- ORCID
- Fan, Timothy M.
- Gorlick, Richard
- Helman, Lee J.
- Kleinerman, Eugenie S.
- Adamson, Peter C.
- Houghton, Peter J.
- Tap, William D.
- Welch, Danny R.
- Steeg, Patricia S.
- Merlino, Glenn
- Sorensen, Poul H.B.
- Meltzer, Paul
- Kirsch, David G.
- Janeway, Katherine A.
- Weigel, Brenda
- Kaplan, Rosandra
- Teicher, Beverly A.
- Seibel, Nita L.
- Smith, Malcolm
- Üren, Aykut
- Patel, Shreyaskumar R.
- Trent, Jeffrey
- Savage, Sharon A.
- Mirabello, Lisa
- Reinke, Denise
- Krailo, Mark
- Bernstein, Mark
- Venue
- Clinical Cancer Research
- Published
- 2014-08-13
- Volume
- 20
- Issue
- 16
- Pages
- 4200-4209
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC4134738
- OpenAlex
- W1974879801
- Cited by
- 178
- References
- 66
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 25 · 2023: 13 · 2022: 6 · 2021: 23 · 2020: 22 · 2019: 13 · 2018: 16 · 2017: 7 · 2016: 20 · 2015: 18 · 2014: 2
- FWCI
- 12.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (ZIABC010566, U10-CA98543, U24CA114766, U10CA180899, U10CA180886, U10CA098543, P30CA016672)
- National Institute of Allergy and Infectious Diseases (K02AI093866)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Veterinary › Small Animals › Veterinary Oncology Research
- Keywords
- osteosarcoma, lung metastasis, metastatic progression, drug development, pharmacodynamic biomarkers, mouse model, micrometastatic disease, mechanism of action
- MeSH terms
- Animals, Antineoplastic Agents, Bone Neoplasms, Disease Models, Animal, Dogs, Drug Evaluation, Preclinical, Humans, Osteosarcoma, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
